Dexmedetomidine administration may be beneficial in relation to ventilator-associated pneumonia Authors: Meixu Wang, Bing Lin, Fei Lin, Mengling Ye Published: 2025 ABSTRACT BackgroundThe impact of Dexmedetomidine (Dex) use on the prognosis of patients with ventilator-associated pneumonia (VAP) remains a subject worthy of further investigation. This study seeks to evaluate the association between Dex administration and prognosis in critically ill patients with VAP. We conducted a retrospective cohort study using the MIMIC-IV database, including adults (≥ 18 years) with VAP and ICU stays ≥ 24 h. Patients were divided into the DEX group and the non-DEX group based on Dex administration. The primary endpoint was in-hospital mortality, and the secondary endpoint was 90-day survival rate. We used multivariable logistic regression and propensity score matching (PSM) to adjust for baseline imbalances. Kaplan-Meier analysis assessed survival differences. Stratified analyses evaluated temporal trends (2008–2022), dosage (mcg/kg/h), and infusion duration (hours) to further validate the robustness of the results. This research included a total of 1766 VAP patients (DEX: n = 905; non-DEX: n = 861), Dex was associated with reduced in-hospital mortality (unadjusted OR 0.55, 95% CI 0.44–0.69; adjusted OR 0.62, 95% CI 0.47–0.83).The survival curve was calculated based on Kaplan-Meier analysis, which indicated that the DEX group exhibited a relatively longer survival time, and this difference was highly statistically significant (p < 0.001).It is worth mentioning that the mortality reduction remained robust across all sensitivity analyses, including PSM, temporal stratification, and dose-duration subgroups. Dex is associated with significantly lower in-hospital mortality in VAP patients.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-33124-1.Keywords: Dexmedetomidine, VAP patients, MIMIC-IV, ICU, In-hospital mortalitySubject terms: Diseases, Medical research, Risk factors Introduction VAP is a nosocomial pneumonia1 that occurs in individuals receiving mechanical ventilation through the application of endotracheal intubation or tracheostomy2. VAP is pneumonia that occurs within 48 h after starting mechanical ventilation or after the interruption of mechanical ventilation3, and is marked by a high prevalence, ranging from 9% to 70% in studies. It is also marked by increased mortality, generally ranging from 20 to 71%4,5. Symptoms of VAP include purulent respiratory secretions, fever, respiratory distress, and radiographic evidence of pulmonary infiltration6, VAP is generally defined by “mechanical injury” and “biological injury,” complicating treatment and leading to elevated mortality, prolonged mechanical ventilation times, and elevated health costs7. Preventive interventions, empirical antimicrobial treatment, and treatments such as combined irrigation and sputum aspiration comprise the primary treatments. These treatments, however, prove ineffective in alleviating symptoms in the early stages of treatment6, prompting the need for the identification of therapeutic targets in order to avoid the onset of VAP. Dexmedetomidine (Dex), a highly selective α2-adrenergic receptor agonist8, possesses a range of actions such as sedation, analgesia, anti-sympathetic activity, anti-inflammatory activity, hemodynamic stability, and delirium and agitation suppression after surgery9, in addition to organ protection10. Because of its safety profile and unique mechanism, it is being increasingly utilized in the clinic. It is now being used for pre-anesthetic medication in pediatric and adult populations, procedural sedation11, anesthesia supplementation, perioperative pain control, and surgery-induced delirium prevention12. Current guidelines suggest Dex as the preferred sedative in ventilated patients, considering that it is effective in sedation and analgesia with hemodynamic stability13. The sedative effect is equivalent to that of midazolam and propofol but with less delirium occurrence14,15. The clinical and research paradigm for Dex is expanding beyond sedation to encompass its significant multi-organ protective effects. Evidence now robustly demonstrates that Dex provides cytoprotection in critical structures such as the heart, brain, lungs, kidneys, liver, and gastrointestinal tract16,17. These pleiotropic benefits are largely mediated through a confluence of key cellular mechanisms: antioxidative stress, potent anti-inflammation, anti-apoptosis, and precise autophagy regulation17,18. Clinical evidence indicates that Dex can reduce the degree of inflammatory mediators in early-stage VAP and enhance lung oxygenation19, thereby exerting a protective function in lung function. Mechanisms behind such effects would be through reduced inflammatory factors, inhibition of the TLRs/NF-κb signal pathways, downregulation of MUC5AC expression, and enhancement in oxidative stress status20. A systematic review of the current evidence suggests21 that Dex possesses a strong sedation, analgesic, and anti-inflammatory potential with the possibility of improving clinical outcomes in VAP patients. However, most such studies were limited by the lack of proper clinical endpoint markers and by having small sample populations—factors critical in establishing the efficacy of interventions against VAP. The precise benefits and the mechanisms through which Dex is effective in VAP treatment, thus, need more in-depth investigation. To more accurately establish the clinical utility of Dex in VAP cases, this study did a retrospective analysis of Intensive care unit (ICU) patient data specifically in VAP-diagnosed cases through the use of the Medical Information Mart for Intensive Care (MIMIC-IV) dataset. Multivariate logistic regression and Kaplan-Meier survival analysis were utilized in this study in order to describe the interaction between administration of Dex and patient outcomes. These types of studies aim to provide novel information about VAP treatment, with the promise of enhancing both treatment efficacy and patient quality of life. Materials and methods Data sources The data used in this study comes from the MIMIC-IV database (version 3.0). This database is extensive and includes de-identified records of over 65,000 intensive care unit admissions and over 200,000 visits to the emergency department from 2008 to 2022 at the Beth Israel Deaconess Medical Center in Boston, Massachusetts. Both the Beth Israel Deaconess Medical Center (Boston, Massachusetts) and the Massachusetts Institute of Technology (Cambridge, Massachusetts) institutional review boards gave their approval for the creation of this database. The MIMIC-IV database has been made available to researcher Lin Bing, who has successfully completed all requirements and been issued a certification by the Cooperative Institutional Training Initiative (CITI) with the number 59,080,615. This study is in alignment with the ethical principles of the Declaration of Helsinki, and the de-identification procedures of the MIMIC-IV database ensure adherence to privacy protection laws, obviating the need for individual informed consent while fulfilling the requisite certification protocols. Research population Inclusion criteria: (1) individuals must be 18 years of age or older; (2) a confirmed diagnosis of VAP in the ICU, as classified by the International Classification of Diseases, Ninth and Tenth Editions (ICD-9 and ICD-10); (3) a minimum duration of ICU admission of 24 h; (4) the presence of comprehensive survival data. The criteria for exclusion are as follows: (1) multiple admissions to the ICU: in cases where a patient has several entries for ICU admissions, only the first admission will be taken into account for this study; (2) ICU stays that are less than 24 h in duration. Within the MIMIC-IV-3.0 database, individuals diagnosed with VAP are categorized using the following codes: “VAP” (code J95851), “VAP” (code 99731), and “Ventilation pneumonitis” (code 4957). Data extraction The process of data extraction utilizes PostgreSQL software (version 15.3) alongside Navicat Premium (version 16.3.2). The subsequent classifications of data have been obtained: (1) Demographic Information: Comprises age, gender, height, weight; (2) Clinical Data: Includes the Acute Physiology Score III (APSIII), SOFA score, Glasgow Coma Scale (GCS) score, administration of vasoactive medications(Including norepinephrine, epinephrine, phenylephrine, dopamine, and vasopressin)22,23. For ease of expression, all were converted to norepinephrine-equivalent doses (obtained using the materialized views provided by the database’s official website), denoted as NE in the text.), and the application of continuous renal replacement therapy (CRRT); (3) Comorbidities: A detailed account of patient comorbidities including myocardial infarction (MI), congestive heart failure (CHF), hypertension, cerebrovascular disease (CAD), chronic pulmonary disease, liver disease, kidney disease, diabetes, and malignant tumors; (4) Key Indicators and Lab Findings: Documentation of the physiological parameters during the initial 24 h in intensive care unit admission is crucial. These include the lowest mean arterial pressure, heart rate (HR), respiratory rate (RR), maximum body temperature, and lowest oxygen saturation. A full assessment of the lab findings is also crucial, such as white blood cell count, percentage of lymphocytes and neutrophils, red cell distribution width, anion gap, level of lactic acid, partial pressure of carbon dioxide and oxygen, partial thromboplastin time, and biochemical parameters such as creatinine, blood urea nitrogen, and urine output. (5) Treatment information: whether patients received Dex therapy, including dosage and duration of Dex administration; dosage and duration of other sedative medications (propofol, midazolam); sedation scores (RASS, Richmond Agitation-Sedation Scale); and antibiotic usage;6.Prognostic information: time of death, in-hospital mortality, duration of mechanical ventilation (MV-Los), length of hospital stay (Hospital-Los, days), ICU stay duration (ICU-Los, hours), and clinical status at a 3-month follow-up. For patients who are admitted to the ICU within a 24-h period, the most unfavorable value of the repeated laboratory indices is documented. Research endpoint This study primarily assesses hospital mortality, with secondary attention to the 90-day survival rate. The data on mortality is derived from the “hospital expire flag” column within the “admissions” table of the MIMIC-IV database. The precise date of death is obtained from the “dod” column in the “patients” table, which synthesizes data from both hospital and state records. Data concerning the 3-month follow-up for all patients are also included. Additional outcome metrics encompass MV-Los, ICU stay duration, and overall hospital stay length. Statistical analyses In this study, some variables had a certain degree of missing data, with detailed data presented in Supplementary Table 1. To ensure the integrity and functionality of the data, multiple imputation was performed utilizing the “mice” package24. Participants were classified into two distinct groups: individuals administered Dex were designated as the experimental group (DEX group), while those not receiving the treatment were allocated to the control group (Non-DEX group). The preliminary examination involved assessing the normal distribution of all continuous variables using the Kolmogorov-Smirnov test. Data that adhered to a normal distribution were represented as mean ± standard deviation (M ± SD), while data that did not conform to this distribution were characterized by the median and interquartile range. Categorical variables were expressed as counts along with their corresponding percentages. The baseline characteristics among the groups were examined to discern any differences. Continuous variables that followed a normal distribution were analyzed using one-way ANOVA, whereas the Mann–Whitney U test was utilized for data that did not conform to normality. For categorical data, the assessment of differences was conducted utilizing the chi-square test. To investigate the correlation between Dex administration and in-hospital mortality, we employed both univariate and multivariate logistic regression analyses, presenting odds ratios and 95% confidence intervals. The investigation encompassed two analytical frameworks: a basic model without adjustments and a multivariate model that incorporated various adjustments. The latter accounted for potential confounding factors identified by a p-value of less than 0.05 in univariate analysis, encompassing clinically significant variables and those associated with prognosis. Model 1 was the unadjusted model; Model 2 adjusted for age, gender, SOFA score, APSIII score, and Charlson comorbidity index (CCI)25. Model 3 incorporated adjustments for a broader set of variables including age, gender, clinical scores, comorbidities, and physiological and laboratory measures.Given that the database included patients from 2008 to 2022 with a substantial time span, we performed additional multivariable regression analyses stratified by different calendar years to account for potential temporal variations in treatment practices. Furthermore, we conducted subgroup analyses by categorizing patients according to quartile ranges of both Dex dosage and duration of administration to further evaluate their differential effects on clinical outcomes. Subgroup analysis was performed employing a hierarchical logistic regression model, stratifying participants by gender, age (≤ 60 years old and > 60 years old), SOFA score (≤ 8 points and > 8 points), use of vasoactive drugs, requirement for CRRT, and the presence of conditions such as malignant tumors, severe liver disease and kidney disease. Odds ratio (OR) and 95% confidence interval (CI) for each subgroup were computed. To evaluate interactions among subgroups, the likelihood ratio test was used, and a forest plot was generated. Additionally, Kaplan–Meier analysis facilitated the creation of cumulative survival curves for patients with follow-up periods extending beyond 90 days in both groups, and the log-rank test assessed differences in survival outcomes. Robustness Testing: To mitigate the influence of confounding variables and selection bias on the results of multivariate analyses, PSM was utilized with a caliper setting of 0.2 and a 1:1 matching ratio between the patient cohorts26. This matching included all variables specified in Model 3. Following matching, logistic regression analysis was conducted on the aligned dataset. Additionally, since the database does not document the exact onset or diagnosis time of VAP, making it difficult to determine whether Dex was administered before or after VAP development, we adopted a conservative analytical strategy. Specifically, we performed additional multivariable analyses by stratifying patients into two subgroups based on Dex initiation timing: within 48 h versus after 48 h of ICU admission, to verify the robustness of our findings. All statistical analyses were performed utilizing the software packages R version 3.4.3 and Stata/MP version 16.0. p < 0.05 were deemed statistically significant. Results Baseline characteristics This study involved a total of 1766 patients diagnosed with VAP. The population was segmented into 905 individuals within the experimental group (DEX group) and 861 within the control group (Non-DEX group) (Fig. 1). The baseline characteristics are presented in Table 1. The median age observed was 62.4 years, with males representing 65.9% (1164) of the entire cohort. Sedation-related outcomes: The two groups had comparable sedation depth (no statistically significant difference in RASS scores). No significant differences were observed between groups in midazolam utilization rate, duration of use, or dose per kilogram per hour (all comparisons P > 0.05). However, the DEX group demonstrated higher propofol utilization rates and longer duration of propofol administration.Antibiotic utilization patterns: The DEX group showed significantly higher usage rates of glycopeptides, cephalosporins, quinolones, nitroimidazoles, carbapenems, and macrolides. No between-group differences were observed for aminoglycosides, β-lactamase inhibitor combinations, or other antibiotic classes.In the analysis of vital signs and laboratory parameters, notable distinctions were identified among the groups across all metrics, with the exception of anion gap, HR, mean arterial pressure, blood glucose, platelet count, white blood cell count, APTT, urine output, and BUN. Variations in comorbid conditions, including CAD and malignant tumors, were observed among the groups. Outcome measures indicated a reduced in-hospital mortality rate in the DEX group, although this was accompanied by prolonged durations of hospitalization, ICU stays, and mechanical ventilation. Study flow chart. Table 1 Baseline characteristics of patients.VariablesTotal (n = 1766)Non-DEX (n = 861)DEX (n = 905) p Gender, n (%)0.002 F602 (34.1)325 (37.7)277 (30.6) M1164 (65.9)536 (62.3)628 (69.4)Age, mean ± SD, year62.4 ± 16.164.9 ± 15.760.1 ± 16.2< 0.001SOFA, mean ± SD8.4 ± 4.07.9 ± 4.19.0 ± 3.9< 0.001NE, n (%)1081 (61.2)504 (58.5)577 (63.8)0.024Charlson index, mean ± SD5.3 ± 2.95.7 ± 2.75.0 ± 3.0< 0.001GCS, mean ± SD8.1 ± 4.28.3 ± 4.37.9 ± 4.10.037APSIII, mean ± SD72.1 ± 27.170.4 ± 27.073.8 ± 27.10.007CRRT, n (%)312 (17.7)111 (12.9)201 (22.2)< 0.001RASS, median (IQR)− 1.4 (− 2.5, − 0.7)− 1.4 (− 2.8, − 0.6)− 1.4 (− 2.3, − 0.8)0.184Midazolam, n (%)841 (47.6)408 (47.4)433 (47.8)0.847MIDtime, median (IQR), hour38.0 (0.6, 121.7)28.9 (0.3, 108.9)45.1 (1.3, 132.5)0.058MIDrate, median (IQR), mcg/kg/h53.7 (30.1, 227.9)50.8 (26.0, 408.1)54.9 (32.0, 119.8)0.573Propofol, n (%)1332 (75.4)625 (72.6)707 (78.1)0.007PROtime, median (IQR), hour87.1 (36.7, 178.5)58.6 (19.5, 120.8)122.1 (60.5, 222.3)< 0.001PROrate, median (IQR), mg/kg/h1.7 (1.2, 2.3)1.7 (1.2, 2.3)1.8 (1.3, 2.3)0.064Antibiotic Glycopeptides, n (%)1561 (88.4)720 (83.6)841 (92.9)< 0.001 Cephalosporins, n (%)1457 (82.5)646 (75)811 (89.6)< 0.001 Quinolones, n (%)570 (32.3)335 (38.9)235 (26)< 0.001 Nitroimidazoles, n (%)520 (29.4)216 (25.1)304 (33.6)< 0.001 Carbapenems, n (%)440 (24.9)160 (18.6)280 (30.9)< 0.001 Macrolides, n (%)307 (17.4)119 (13.8)188 (20.8)< 0.001 Aminoglycosides, n (%)216 (12.2)109 (12.7)107 (11.8)0.592 β-lactamase inhibitor combinations, n (%)703 (39.8)353 (41)350 (38.7)0.318 Others, n (%)493 (27.9)229 (26.6)264 (29.2)0.228Aniongap, mean ± SD, mmol/L16.8 ± 5.216.8 ± 5.316.8 ± 5.10.773Bicarbonate, mean ± SD, mmol/L24.2 ± 4.724.5 ± 4.724.0 ± 4.70.013Heart rate, mean ± SD107.3 ± 21.3106.5 ± 21.1108.0 ± 21.40.136MBP, mean ± SD, mmHg58.1 ± 14.258.3 ± 14.358.0 ± 14.00.613Respiratory rate, mean ± SD29.1 ± 6.828.3 ± 6.429.7 ± 7.1< 0.001Spo2, mean ± SD91.3 ± 7.091.8 ± 6.790.9 ± 7.30.006Temperature, mean ± SD, °C37.0 ± 0.837.0 ± 0.837.1 ± 0.8< 0.001Weight, median (IQR), kg85.0 (71.0, 100.0)81.0 (69.0, 98.0)88.0 (73.0, 104.0)< 0.001Glucose, median (IQR), mg/dl143.0 (118.0, 174.0)142.0 (118.0, 173.0)143.0 (118.0, 175.0)0.991Platelets, median (IQR), 109/L175.0 (119.2, 235.0)175.0 (118.0, 234.0)175.0 (122.0, 237.0)0.501WBC, median (IQR), 109/L15.0 (11.0, 19.0)14.0 (10.0, 19.0)15.0 (11.0, 19.0)0.052PT, median (IQR), s14.0 (13.0, 17.0)14.0 (13.0, 17.0)14.0 (13.0, 17.0)0.017APTT, median (IQR), s33.0 (28.0, 49.0)33.0 (28.0, 48.0)32.0 (28.0, 49.0)0.651Urineoutput, median (IQR), ml1522.5 (892.8, 2343.8)1500.0 (930.0, 2360.0)1545.0 (870.0, 2325.0)0.57BUN, median (IQR), µmol/L23.0 (15.2, 37.0)23.0 (15.0, 37.0)23.0 (16.0, 36.0)0.445Creatinine, median (IQR), mg/dl1.0 (1.0, 2.0)1.0 (1.0, 2.0)1.0 (1.0, 2.0)< 0.001Myocardial infarct, n (%)0.842 No1453 (82.3)710 (82.5)743 (82.1) Yes313 (17.7)151 (17.5)162 (17.9)Congestive heart failure, n (%)0.349 No1247 (70.6)599 (69.6)648 (71.6) Yes519 (29.4)262 (30.4)257 (28.4)Cerebrovascular disease, n (%)< 0.001 No1322 (74.9)613 (71.2)709 (78.3) Yes444 (25.1)248 (28.8)196 (21.7)Chronic pulmonary disease, n (%)0.734 No1315 (74.5)638 (74.1)677 (74.8) Yes451 (25.5)223 (25.9)228 (25.2)Diabetes complicated, n (%)0.279 No1590 (90.0)782 (90.8)808 (89.3) Yes176 (10.0)79 (9.2)97 (10.7)Renal disease, n (%)0.614 No1434 (81.2)695 (80.7)739 (81.7) Yes332 (18.8)166 (19.3)166 (18.3)Severe liver disease, n (%)0.837 No1635 (92.6)796 (92.5)839 (92.7) Yes131 ( 7.4)65 (7.5)66 (7.3)Malignant cancer, n (%)0.028 No1616 (91.5)775 (90)841 (92.9) Yes150 ( 8.5)86 (10)64 (7.1)MV-LOS, median (IQR), hour152.0 (64.0, 274.0)95.0 (38.0, 198.0)206.0 (112.0, 340.0)< 0.001H-LOS, mean ± SD, day27.8 ± 21.625.3 ± 20.330.2 ± 22.5< 0.001ICU-LOS, mean ± SD, day17.2 ± 13.514.1 ± 11.420.1 ± 14.7< 0.001Hospital mortality, n (%)423 (24.0)254 (29.5)169 (18.7)< 0.001Data presented are Mean ± SD or median(Q1–Q3) or n (%).SOFA: Sequential organ failure assessment, NE: norepinephrine, GCS: Glasgow Coma Scale, APSIII: Acute Physiology Score III, CRRT: continuous renal replacement therapy, BUN: blood urea nitrogen, WBC: white blood cell, MBP: mean blood pressure, SPO2: saturation of peripheral oxygen, LOS: length of stay, H-LOS: hospital-LOS, MV: mechanical ventilation, RASS: Richmond agitation-Sedation Scale, MIDtime: duration of midazolam, MIDrate: midazolam infusion rate, PROtime: duration of propofol, PROrate: propofol infusion rate. Baseline characteristics of patients. Data presented are Mean ± SD or median(Q1–Q3) or n (%). SOFA: Sequential organ failure assessment, NE: norepinephrine, GCS: Glasgow Coma Scale, APSIII: Acute Physiology Score III, CRRT: continuous renal replacement therapy, BUN: blood urea nitrogen, WBC: white blood cell, MBP: mean blood pressure, SPO2: saturation of peripheral oxygen, LOS: length of stay, H-LOS: hospital-LOS, MV: mechanical ventilation, RASS: Richmond agitation-Sedation Scale, MIDtime: duration of midazolam, MIDrate: midazolam infusion rate, PROtime: duration of propofol, PROrate: propofol infusion rate. Univariate logistic analysis and multivariable logistic regression models Initially, a univariate logistic regression analysis was conducted to identify factors linked to in-hospital mortality among patients with VAP (Supplementary Table 2). Various factors, including gender, HR, mean arterial pressure, RR, SPO2 levels, dosage and duration of midazolam and propofol administration, chronic pulmonary disease, complications from diabetes, glucose, and platelet count, exhibited weak correlations with in-hospital mortality (p ≥ 0.05). Although gender, platelet count, and blood glucose did not meet the statistical significance threshold, they were included as covariates in the multivariable analysis alongside all variables with p < 0.05, were incorporated as covariates in the multivariate analysis. The comprehensive list of covariates included age, gender, SOFA score, APSIII score, CCI, GCS score, use of vasoactive drugs, CRRT, RASS, weight, presence of malignant tumor, severe liver disease, MI, CHF, kidney disease, CAD, body temperature, anion gap, bicarbonate, BUN, creatinine, platelets, blood glucose, white blood cell count, coagulation time, urine volume, and mechanical ventilation duration. The results from the multivariate logistic regression analysis are presented in Table 2. The unadjusted model (Model 1) revealed that Dex administration correlated with a decrease in in-hospital mortality among VAP patients [OR 0.55 (95% CI 0.44–0.69)]. Following adjustments for all confounding variables, the association continued to hold significance, as illustrated in Model 3, where the adjusted OR for in-hospital mortality in the DEX group was 0.62 (0.47–0.83). Table 2Multivariable logistic regression models evaluating the association between DEX and hospital mortality.DEXOR95% CIP valueCrude0.550.44–0.69< 0.001Model 10.550.43–0.70< 0.001Model 20.620.47–0.830.001The control group is the non-DEX group Model 1 adjust confounding variables: age, gender, SOFA score, APSIII score, and Charlson comorbidity index.Model 2 adjust confounding variables: model 1 + GCS score, vasoactive drugs, CRRT, RASS, weight, malignant tumor, severe liver disease, myocardial infarction, congestive heart failure, kidney disease, cerebrovascular disease, body temperature, anion gap, bicarbonate, BUN, creatinine, platelets, blood glucose, white blood cells, coagulation time, urine volume, and mechanical ventilation time. Multivariable logistic regression models evaluating the association between DEX and hospital mortality. The control group is the non-DEX group Model 1 adjust confounding variables: age, gender, SOFA score, APSIII score, and Charlson comorbidity index. Model 2 adjust confounding variables: model 1 + GCS score, vasoactive drugs, CRRT, RASS, weight, malignant tumor, severe liver disease, myocardial infarction, congestive heart failure, kidney disease, cerebrovascular disease, body temperature, anion gap, bicarbonate, BUN, creatinine, platelets, blood glucose, white blood cells, coagulation time, urine volume, and mechanical ventilation time. Subgroup analysis The analysis, illustrated in Fig. 2, identified a significant interaction between the administration of norepinephrine and the efficacy of Dex in reducing in-hospital mortality (interaction p-value = 0.036). Notably, Dex administration substantially decreased in-hospital mortality for patients receiving norepinephrine, with an OR of 0.41 compared to 0.56. Stratified analyses indicated that all subgroups, except those with concurrent MI, malignant tumors, and severe liver diseases—which showed an OR (95% CI) including 1—benefited from Dex treatment with a reduction in in-hospital mortality.Given that the database included patients from 2008 to 2022 with a substantial time span, we conducted additional multivariable regression analyses stratified by different calendar years to account for potential temporal variations in treatment practices. The results are presented in Table 3. The findings demonstrate that when analyzed by three distinct chronological groupings, the DEX group consistently showed lower mortality rates (OR < 1, p < 0.05) across all time periods. Furthermore, all P-values for interaction exceeded 0.05, indicating no significant effect modification by time period on the association between Dex and mortality. Forest plot for subgroup analysis for the association between DEX and hospital mortality. Table 3 The association between DEX and hospital mortality was assessed after grouping patients by their different years of admission.VariableTotal (n)Hospital mortality n (%)Crude.OR (95% CI)Crude PAdj.OR (95% CI)Adj.PP for interactionSubgroup1 2008–20160.954 Non-DEX669174 (26.0%)1(Ref)1(Ref) DEX40660 (14.8%)0.49 (0.36–0.68)< 0.0010.56 (0.37–0.83)0.004 2017–2022Non-DEX19280 (41.7%)1(Ref)1(Ref)DEX499109 (21.8%)0.39 (0.27–0.56)< 0.0010.59 (0.37–0.96)0.034Subgroup2 2008–20130.256 Non-DEX497127 (25.6%)1(Ref)1(Ref) DEX23829 (12.2%)0.4 (0.26–0.63)< 0.0010.39 (0.22–0.68)0.001 2014–2022 Non-DEX364127 (34.9%)1(Ref)1(Ref) DEX667140 (21.0%)0.5 (0.37–0.66)< 0.0010.66 (0.45–0.95)0.025Subgroup3 2008–20130.445 Non-DEX497127 (25.6%)1(Ref)1(Ref) DEX23829 (12.2%)0.4 (0.26–0.63)< 0.0010.39 (0.22–0.68)0.001 2017–2022 Non-DEX19280 (41.7%)1(Ref)1(Ref) DEX499109 (21.8%)0.39 (0.27–0.56)< 0.0010.59 (0.37–0.96)0.034Adjust confounding variables: age, gender, SOFA score, APSIII score, and Charlson comorbidity index, GCS score, vasoactive drugs, CRRT, RASS, weight, malignant tumor, severe liver disease, myocardial infarction, congestive heart failure, kidney disease, cerebrovascular disease, body temperature, anion gap, bicarbonate, BUN, creatinine, platelets, blood glucose, white blood cells, coagulation time, urine volume, and mechanical ventilation time. The association between DEX and hospital mortality was assessed after grouping patients by their different years of admission. Adjust confounding variables: age, gender, SOFA score, APSIII score, and Charlson comorbidity index, GCS score, vasoactive drugs, CRRT, RASS, weight, malignant tumor, severe liver disease, myocardial infarction, congestive heart failure, kidney disease, cerebrovascular disease, body temperature, anion gap, bicarbonate, BUN, creatinine, platelets, blood glucose, white blood cells, coagulation time, urine volume, and mechanical ventilation time. Survival analysis Throughout this study, comprehensive 90-day survival data were available for all participants. Survival curves were constructed to provide a clear visual representation of the survival trends over time for these patients. As illustrated in Fig. 3, the survival curves for the DEX group (Dex = 1) and the Non-DEX group (Dex = 0) exhibited a significant divergence, with the DEX group showing markedly extended survival durations. The observed difference reached statistical significance (p < 0.001), highlighting the possible survival advantages of Dex in patients with VAP. Kaplan–Meier survival curves of patients with VAP. Impact of Dex dosage and duration on outcomes We stratified patients by quartile ranges of Dex dosage and duration of administration to evaluate their effects on in-hospital mortality, as shown in Table 4. Duration of Dex administration: Groups with Dex duration < 153.5 h (all three lower quartiles) showed significantly lower in-hospital mortality (P < 0.05).Dex dosage: The two middle dosage groups (0.353–0.962 mcg/kg/h) demonstrated significantly reduced in-hospital mortality (P < 0.05).Trend analysis: Both dosage and duration exhibited statistically significant trends (P for trend < 0.05), indicating a consistent association between Dex use and lower in-hospital mortality. Table 4Duration-response and dose-response relationships between Dex administration and hospital mortality.Total (n)Hospital mortality n (%)Adj.OR (95% CI)Adj.P valueDuration of Dex (hour) Non-DEX861254 (29.5)1(Ref) < 21.522637 (16.4)0.55 (0.35−0.86)0.008 21.5–69.522644 (19.5)0.64 (0.42−0.98)0.041 69.5-153.522636 (15.9)0.61 (0.39−0.97)0.038 ≥ 153.522752 (22.9)0.72 (0.45−1.15)0.174 Trend.test1766423 (24)0.89 (0.8−0.98)0.022Dex infusion rate (mcg/kg/h) Non-DEX861254 (29.5)1(Ref) < 0.35322752 (22.9)0.72 (0.46−1.11)0.138 0.353–0.62322639 (17.3)0.54 (0.35−0.84)0.006 0.623–0.96222642 (18.6)0.57 (0.36−0.88)0.012 > 0.96222636 (15.9)0.7 (0.44−1.12)0.133 Trend.test1766423 (24)0.87 (0.78−0.96)0.005The control group is the Non-DEX group.Adjust confounding variables: age, gender, SOFA score, APSIII score, and Charlson comorbidity index, GCS score, vasoactive drugs, CRRT, RASS, weight, malignant tumor, severe liver disease, myocardial infarction, congestive heart failure, kidney disease, cerebrovascular disease, body temperature, anion gap, bicarbonate, BUN, creatinine, platelets, blood glucose, white blood cells, coagulation time, urine volume, and mechanical ventilation time. Duration-response and dose-response relationships between Dex administration and hospital mortality. The control group is the Non-DEX group. Adjust confounding variables: age, gender, SOFA score, APSIII score, and Charlson comorbidity index, GCS score, vasoactive drugs, CRRT, RASS, weight, malignant tumor, severe liver disease, myocardial infarction, congestive heart failure, kidney disease, cerebrovascular disease, body temperature, anion gap, bicarbonate, BUN, creatinine, platelets, blood glucose, white blood cells, coagulation time, urine volume, and mechanical ventilation time. Robustness test To rigorously control for confounding variables in this study, PSM was employed for both patient groups. The caliper was set at 0.2, and the matching ratio was maintained at 1:1. The matching included all variables outlined in Model 3. After implementing PSM, 559 pairs of patients were successfully matched, totaling 1118 individuals27. The baseline characteristics of these patients are detailed in Table 5. Post-matching, an assessment of the baseline data—encompassing demographic information, disease severity, RASS scores, vital signs, laboratory tests, and comorbidity profiles—demonstrated effective equivalence between the two groups, with no significant differences in these baseline characteristics (all p values > 0.05). Outcome measures revealed distinctive results for the DEX group, which exhibited a lower in-hospital mortality rate but longer durations of mechanical ventilation compared to the Non-DEX group. Subsequent analyses, including univariate and multivariate regression on the matched dataset, are summarized in Table 6. These analyses showed that Dex significantly lowered in-hospital mortality [OR 0.59 (95%CI 0.42–0.83)]. Additionally, as the database did not label the specific onset time and diagnosis time of ventilator-associated pneumonia (VAP), it was challenging to distinguish whether Dex was administered before or after the occurrence of VAP. A conservative analytical strategy was therefore adopted. Patients were grouped based on whether Dex was initiated within 48 h or after 48 h of ICU admission. Multivariate analysis was then conducted again, and the results are presented in Table 7. Compared with the Non-DEX group, the use of Dex, whether initiated within 48 h or after 48 h of ICU admission, was associated with a lower in-hospital mortality rate (OR < 1, p < 0.05). Moreover, the p-value for trend in the trend test was less than 0.05, indicating that the results were robust and reliable. Table 5 Post-PSM baseline table of patients.VariablesTotal (n = 1118)Non-DEX (n = 559)DEX (n = 559) p Gender, n (%)0.800 F378 (33.8)191 (34.2)187 (33.5) M740 (66.2)368 (65.8)372 (66.5)Age, mean ± SD, year62.2 ± 16.462.2 ± 16.162.1 ± 16.60.919SOFA, mean ± SD8.4 ± 4.08.4 ± 4.28.3 ± 3.90.773NE, n (%)710 (63.5)345 (61.7)365 (65.3)0.214RASS, median (IQR)− 1.4 (− 2.3, − 0.7)− 1.3 (− 2.5, − 0.6)− 1.4 (− 2.2, − 0.8)0.746Charlson index, mean ± SD5.3 ± 2.95.4 ± 2.75.3 ± 3.00.787GCS, mean ± SD8.2 ± 4.28.1 ± 4.28.4 ± 4.10.257APSIII, mean ± SD71.5 ± 27.072.1 ± 27.770.8 ± 26.30.409CRRT, n (%)171 (15.3)87 (15.6)84 (15)0.803Aniongap, mean ± SD, mmol/L17.0 ± 5.116.8 ± 5.017.1 ± 5.20.238Bicarbonate, mean ± SD, mmol/L24.3 ± 4.524.3 ± 4.524.3 ± 4.60.849Heart rate, mean ± SD108.0 ± 21.0107.6 ± 20.8108.5 ± 21.30.479MBP, mean ± SD, mmHg57.6 ± 14.358.1 ± 14.457.2 ± 14.30.312Respiratory rate, mean ± SD29.2 ± 7.028.9 ± 6.629.4 ± 7.30.235Spo2, mean ± SD91.3 ± 7.191.2 ± 7.191.3 ± 7.20.838Temperature, mean ± SD, °C37.0 ± 0.837.0 ± 0.837.1 ± 0.80.391Weight, mean ± SD, kg88.5 ± 26.788.8 ± 26.288.3 ± 27.20.752Glucose, mean ± SD, mg/dl153.2 ± 51.1152.4 ± 51.5154.0 ± 50.80.590Platelets, mean ± SD, 109/L184.3 ± 100.1185.7 ± 106.0182.9 ± 94.00.640WBC, median (IQR), 109/L15.0 (11.0, 19.0)15.0 (10.0, 19.0)15.0 (11.0, 19.0)0.430PT, mean ± SD, s16.9 ± 10.816.9 ± 8.117.0 ± 12.90.879APTT, median (IQR), s33.0 (28.0, 49.8)33.0 (28.0, 50.0)32.0 (28.0, 49.0)0.517Urineoutput, median (IQR), ml1565.0 (911.2, 2348.8)1525.0 (890.0, 2360.0)1625.0 (923.0, 2327.0)0.547BUN, median (IQR), µmol/L23.0 (15.0, 36.0)23.0 (15.0, 37.0)22.0 (16.0, 35.0)0.798Creatinine, median (IQR), mg/dl1.0 (1.0, 2.0)1.0 (1.0, 2.0)1.0 (1.0, 2.0)0.207Myocardial infarct, n (%)0.353 No914 (81.8)451 (80.7)463 (82.8) Yes204 (18.2)108 (19.3)96 (17.2)Congestive heart failure, n (%)0.947 No797 (71.3)398 (71.2)399 (71.4) Yes321 (28.7)161 (28.8)160 (28.6)Cerebrovascular disease, n (%)0.724 No855 (76.5)425 (76)430 (76.9) Yes263 (23.5)134 (24)129 (23.1)Chronic pulmonary disease, n (%)0.946 No823 (73.6)412 (73.7)411 (73.5) Yes295 (26.4)147 (26.3)148 (26.5)Diabetes complicated, n (%)0.537 No833 (74.5)421 (75.3)412 (73.7) Yes285 (25.5)138 (24.7)147 (26.3)Renal disease, n (%)0.760 No906 (81.0)455 (81.4)451 (80.7) Yes212 (19.0)104 (18.6)108 (19.3)Severe liver disease, n (%)0.822 No1032 (92.3)515 (92.1)517 (92.5) Yes86 ( 7.7)44 (7.9)42 (7.5)Malignant cancer, n (%)0.595 No1021 (91.3)513 (91.8)508 (90.9) Yes97 ( 8.7)46 (8.2)51 (9.1)MV-LOS, median (IQR), hour144.5 (64.2, 242.0)127.0 (50.0, 251.5)150.0 (81.0, 236.5)0.047H-LOS, median (IQR), day22.0 (15.0, 31.0)22.0 (14.0, 32.0)21.0 (15.0, 30.0)0.807ICU-LOS, median (IQR), day14.0 (8.0, 21.0)14.0 (7.0, 22.0)14.0 (9.0, 20.0)0.560Hospital mortality, n (%)254 (22.7)148 (26.5)106 (19.0)0.003Data presented are mean ± SD or median(Q1–Q3) or n (%).SOFA: Sequential organ failure assessment, NE: norepinephrine, RASS: Richmond agitation-Sedation Scale, GCS: Glasgow Coma Scale, APSIII: Acute Physiology Score III, CRRT: continuous renal replacement therapy, BUN: blood urea nitrogen, WBC: white blood cell, MBP: mean blood pressure, SPO2: saturation of peripheral oxygen, LOS: length of stay, H-LOS: hospital-LOS, MV: mechanical ventilation. Post-PSM baseline table of patients. Data presented are mean ± SD or median(Q1–Q3) or n (%). SOFA: Sequential organ failure assessment, NE: norepinephrine, RASS: Richmond agitation-Sedation Scale, GCS: Glasgow Coma Scale, APSIII: Acute Physiology Score III, CRRT: continuous renal replacement therapy, BUN: blood urea nitrogen, WBC: white blood cell, MBP: mean blood pressure, SPO2: saturation of peripheral oxygen, LOS: length of stay, H-LOS: hospital-LOS, MV: mechanical ventilation. Table 6Univariate and multivariate analyses affecting hospital mortality in VAP patients after PSM.VariableUnivariate analysisMultivariate analysisOR (95% CI) p OR (95% CI) p DEX 0.65 (0.49–0.86) 0.003 0.59 (0.42–0.83) 0.002 Male1.07 (0.79–1.44)0.6641.06 (0.74–1.5)0.762Age1.04 (1.03–1.05)< 0.0011.04 (1.03–1.06)< 0.001SOFA1.09 (1.05–1.12)< 0.0010.96 (0.9–1.02)0.209RASS0.53 (0.47–0.6)< 0.0010.46 (0.39–0.54)< 0.001NE1.39 (1.03–1.88)0.0300.91 (0.62–1.35)0.651Charlson index1.18 (1.12–1.24)< 0.0011.04 (0.95–1.14)0.425GCS0.94 (0.91–0.98)0.0011.04 (0.97–1.11)0.257APSIII1.02 (1.01–1.02)< 0.0011 (0.99–1.02)0.500CRRT3.91 (2.77–5.5)< 0.0012.5 (1.53–4.09)< 0.001Platelets1 (1–1)0.579WBC1.01 (1–1.03)0.056Aniongap1.03 (1.01–1.06)0.0160.99 (0.96–1.03)0.615Bicarbonate0.98 (0.95–1.01)0.178BUN1.02 (1.01–1.02)< 0.0011.01 (1–1.02)0.104Creatinine1.1 (1.02–1.2)0.0150.87 (0.74–1.03)0.104PT1.02 (1.01–1.03)0.0051.01 (1–1.03)0.057APTT1 (1–1.01)0.0271 (0.99–1)0.757Urineoutput1 (1–1)< 0.0011 (1–1)0.271Heart rate1 (0.99–1)0.161MBP1 (0.99–1.01)0.403Respiratory rate1.02 (1–1.04)0.0251.02 (0.99–1.04)0.225SPO20.98 (0.96–1)0.0360.98 (0.96–1.01)0.232Temperature0.67 (0.56–0.8)< 0.0010.78 (0.62–0.97)0.024Glucose1 (1–1)0.161Weight1 (0.99–1)0.122Myocardial infarct1.74 (1.24–2.44)0.0011.15 (0.74–1.8)0.529Congestive heart failure1.89 (1.41–2.54)< 0.0011.54 (1.03–2.31)0.035Cerebrovascular disease1.32 (0.96–1.82)0.085Chronic pulmonary disease1.42 (1.05–1.93)0.0241.09 (0.75–1.59)0.643Diabetes complicated1.15 (0.84–1.57)0.390Renal disease1.83 (1.31–2.54)< 0.0011.07 (0.65–1.74)0.801Severe liver disease1.82 (1.14–2.92)0.0122.67 (1.41–5.08)0.003Malignant cancer1.59 (1.01–2.51)0.0451.94 (1.1–3.42)0.023Significant values are in bold. Univariate and multivariate analyses affecting hospital mortality in VAP patients after PSM. Significant values are in bold. Table 7 The results of multivariate analysis grouped by Dex usage time.VariableN.totalN.hospital mortality(%)Crude.OR (95%CI)Crude PAdj.OR (95%CI)Adj.PNon-DEX861254 (29.5)1(Ref)1(Ref)DEX ≤ 48 h20629 (14.1)0.39 (0.26–0.6)< 0.0010.54 (0.33–0.88)0.014DEX > 48 h699140 (20)0.6 (0.47–0.76)< 0.0010.65 (0.48–0.88)0.005Trend.test1766423 (24)0.76 (0.67–0.86)< 0.0010.8 (0.68–0.93)0.003DEX ≤ 48 h: Dex initiated within 48 h of ICU admission.DEX > 48 h: Dex initiated beyond 48 h of ICU admission.Adjust confounding variables: age, gender, SOFA score, APSIII score, and Charlson comorbidity index, GCS score, vasoactive drugs, CRRT, RASS, weight, malignant tumor, severe liver disease, myocardial infarction, congestive heart failure, kidney disease, cerebrovascular disease, body temperature, anion gap, bicarbonate, BUN, creatinine, platelets, blood glucose, white blood cells, coagulation time, urine volume, and mechanical ventilation time The results of multivariate analysis grouped by Dex usage time. DEX ≤ 48 h: Dex initiated within 48 h of ICU admission. DEX > 48 h: Dex initiated beyond 48 h of ICU admission. Adjust confounding variables: age, gender, SOFA score, APSIII score, and Charlson comorbidity index, GCS score, vasoactive drugs, CRRT, RASS, weight, malignant tumor, severe liver disease, myocardial infarction, congestive heart failure, kidney disease, cerebrovascular disease, body temperature, anion gap, bicarbonate, BUN, creatinine, platelets, blood glucose, white blood cells, coagulation time, urine volume, and mechanical ventilation time Discussion This MIMIC-IV database retrospective study illustrates that Dex administration is linked with reduced mortality among VAP inpatients during their in-hospital stay. When compared with non-Dex-treated individuals, Dex-treated individuals had a lower in-hospital mortality rate, with an OR of 0.62 (95% CI 0.47–0.83), and with significantly extended survival durations. This correlation remained consistent across subgroup analyses and propensity score matching (PSM) analysis, indicating the robustness of the results. However, the DEX group had longer durations of mechanical ventilation and hospital stay. which might be attributable to the relatively more severe condition of patients in this group, as evidenced by higher Sequential Organ Failure Assessment (SOFA) scores and Acute Physiology and Chronic Health Evaluation III (APSIII) scores, a greater proportion of patients requiring norepinephrine support and continuous renal replacement therapy (CRRT), and lower Glasgow Coma Scale (GCS) scores. Subgroup analyses revealed that except for patients with comorbid myocardial infarction, malignant tumors, or severe liver diseases, all other subgroups benefited from Dex treatment in terms of reduced in-hospital mortality. As seen from the baseline table, the DEX group had more extensive use of broad-spectrum antibiotics (such as carbapenems, glycopeptides, third-generation cephalosporins, etc.)28. In contrast, the Non-DEX group had a narrower spectrum of antibiotic use, with relatively more quinolones (which may reflect a higher proportion of community-acquired infections). Despite the DEX group exhibiting the following higher-risk characteristics: more severe illness (higher Sequential Organ Failure Assessment (SOFA) scores, greater use of norepinephrine (NE)) and a heavier infectious burden (more extensive use of broad-spectrum antibiotics), the in-hospital mortality rate in this group was still significantly lower. This finding: reinforces the protective effect of Dex—even in more critically ill patients, Dex can significantly reduce mortality. It suggests that the benefits of Dex may extend beyond its mere sedative effects—its anti-inflammatory, organ-protective, and other mechanisms may be particularly crucial for patients with severe infections. The Richmond Agitation-Sedation Scale (RASS) is used as a tool to assess the depth of sedation. The absence of a statistically significant difference in RASS scores between the two groups indicates that the levels of sedation were similar. However, the mortality rate in the DEX group was significantly lower than that in the Non-DEX group (18.7% vs. 29.5%). This phenomenon may be related to the anti-inflammatory and lung-protective effects of Dex. Under a personalized sedation strategy aimed at achieving mild sedation, the suppression of respiratory and circulatory functions can be minimized while maintaining patient comfort and cooperation. By implementing a personalized sedation strategy and using Dex, the incidence of complications in patients with ventilator-associated pneumonia (VAP) can be reduced. For example, it can decrease the occurrence of psychiatric symptoms such as delirium and agitation, as well as lower the risk of accidental extubation. The occurrence of these complications not only affects the treatment efficacy and prognosis of patients but also increases healthcare costs and nursing burdens. The temporal stability analysis in Table 5 demonstrated consistent clinical benefits of Dex across all three time-stratified models (2008–2016/2017–2022, 2008–2013/2014–2022, and 2008–2013/2017–2022), with significantly lower in-hospital mortality in the DEX group versus Non-DEX controls (all P < 0.05). The non-significant interaction terms (all P for interaction > 0.05: 0.954/0.256/0.445) confirmed the temporal consistency of Dex’s therapeutic benefits.These findings robustly validate the sustained clinical efficacy of Dex across different treatment eras. Through rigorous time-stratified analyses, this study provides high-level evidence supporting the enduring clinical value of Dex over a 15-year span, establishing its long-term utility in critical care medicine. In the subgroup analysis of Dex dosage and duration, all groups with Dex duration < 153.5 h showed significantly reduced mortality (P < 0.05). However, as the duration of use increased, the protective effect showed a trend of weakening. The 153.5-h mark may represent a critical turning point, as the group with a duration ≥ 153.5 h (P = 0.174) lost statistical significance. In the dose-response relationship analysis, the dose range of 0.353–0.962 mcg/kg/h exhibited the strongest protective effect (OR 0.54–0.57, P < 0.05). It is recommended to control the Dex dosage within the range of 0.353–0.962 mcg/kg/h and limit the duration of use to no more than 153.5 h (approximately 6.5 days), as exceeding these limits may diminish clinical benefits. Therefore, a moderate dose of Dex, achieving an optimal balance between sedation depth, anti-inflammatory effects, and adverse reactions, may confer significant benefits by reducing in-hospital mortality. Given the absence of documented VAP onset/diagnosis times in the database, we implemented a conservative analytical approach by stratifying patients based on Dex initiation timing (≤ 48 h vs. >48 h after ICU admission). Key findings from this time-stratified analysis include: the early-use group (≤ 48 h) demonstrated an absolute reduction in mortality of 15.4% (from 29.5% to 14.1%), while the late-use group (> 48 h) showed an absolute reduction of 9.5% (from 29.5% to 20%). Potential mechanisms: Preemptive anti-inflammatory effects (blocking cytokine cascades)Reduction of early sedation-related complications.Persistent benefits may derive from: its ability to block ongoing anti-sympathetic storm effects, its immunomodulatory actions, and indirect benefits derived from preventing delirium, among other factors. Possible mechanisms VAP occurs in patients more than 48 h after mechanical ventilation via tracheal intubation or tracheotomy. The pathogenesis of VAP involves two main mechanisms: firstly, volume trauma from ventilation-related airway pressure can cause diffuse damage to the alveolar-capillary membrane and increase its permeability29, secondly, the aggressive mechanical stretching by the ventilator triggers the release of inflammatory mediators from lung resident cells, which promotes the transcription and expression of pro-inflammatory factors, initiating an inflammatory cascade that results in lung injury30. Consequently, the primary treatment strategies for VAP focus on preventive measures, along with empirical anti-inflammatory therapies, anti-infection approaches, and alveolar lavage via fiber bronchoscopy. Recent studies have highlighted the pulmonary protective effects of Dex in various contexts of lung injury31, including its influence on pulmonary vascular contraction mechanisms, mitigation of ischemia-reperfusion injury, and modulation of inflammatory cytokine release. As an α(2)-adrenergic receptor agonist, Dex has been shown to reduce the synthesis of inflammatory mediators in the body and inhibit the activation of the TLRs/NF-κB signal transduction32, proving effective in VAP management. Through increased oxidative stress response, Dex significantly increases oxygenation in the lung and maintains lung function, which, in addition to minimizing the frequency of multiple organ dysfunction syndrome (MODS) in patients, results in reduced in-hospital mortality. Strengths and limitations Currently, clinical investigations into Dex for VAP suggest its potential to reduce inflammatory mediator levels, improve respiratory mechanics, and enhance pulmonary oxygenation in the early stages of the condition. These mechanisms may contribute to lung protection and potentially decrease the incidence of MODS. However, these studies often lack consideration of clinical endpoint indicators and are constrained by small sample sizes, which casts uncertainty on whether Dex truly enhances VAP prognosis33,34. In contrast, the present study addresses these gaps by focusing specifically on the high-risk VAP population and leveraging a large, real-world cohort from the authoritative MIMIC-IV database. To our knowledge, this is the first study to comprehensively assess the association between Dex and clinically pivotal outcomes—specifically in-hospital mortality and survival time—in VAP patients, while rigorously adjusting for numerous confounding factors. Furthermore, our work is pioneering in its extensive subgroup and sensitivity analyses, which reinforce the robustness of the findings. Collectively, our results corroborate that Dex may serve as a protective factor in VAP, providing a foundational evidence base for future prospective studies aimed at optimizing its use in this vulnerable patient group. Despite these strengths, the study is not without its limitations: (1) The retrospective nature of the study limits the ability to establish causality and may introduce selection bias. For instance, the decision to administer Dex may be influenced by clinical factors such as sedation requirements and hemodynamic stability, and physician preference, which could confound the observed outcomes. Additionally, due to the lack of chest computed tomography (CT) images in the database, we could not conduct imaging scoring for pneumonia, which is known to correlate with prognosis; (2) The inclusion of VAP patients relied on diagnostic codes, which may not have captured all cases and could be subject to misclassification. Furthermore, the definition of VAP has evolved over time, which may affect the consistency of the diagnosis across the study period. However, due to the inherent structure of the MIMIC database, beyond relying on diagnostic codes, it was not feasible to extract additional clinical data to determine whether patients had concurrent VAP; (3) Significant data loss led to the exclusion of some prognostically important indicators such as hemoglobin, blood lactic acid, oxygenation index, electrolytes, and albumin levels, where the missing data rate was over 20%. Substantial missing data for certain prognostic indicators may affect the validity of our conclusions, despite our use of multiple imputation methods. Future perspectives Our study’s reliance on diagnostic codes for VAP case identification underscores the need for more rigorous validation in future research. To address this and other complexities of VAP, subsequent investigations should focus on: Validation through Prospective Trials: Conducting prospective, multicenter randomized controlled trials that employ standardized, clinical VAP diagnostic criteria (rather than administrative codes) to conclusively validate the association between Dex and patient outcomes. Validation through Prospective Trials: Conducting prospective, multicenter randomized controlled trials that employ standardized, clinical VAP diagnostic criteria (rather than administrative codes) to conclusively validate the association between Dex and patient outcomes. Dosage Optimization: Establishing the specific and optimal dosage and timing of Dex administration in critically ill patients with VAP. Dosage Optimization: Establishing the specific and optimal dosage and timing of Dex administration in critically ill patients with VAP. Exploration of Synergy: Investigating the potential for synergistic effects when Dex is combined with other therapeutic strategies, such as novel antimicrobials or immunomodulators, to develop a more comprehensive management approach. Exploration of Synergy: Investigating the potential for synergistic effects when Dex is combined with other therapeutic strategies, such as novel antimicrobials or immunomodulators, to develop a more comprehensive management approach. Conclusion Based on our findings, Dex appears to reduce in-hospital mortality and extend survival times in VAP patients. Consequently, additional clinical trials are warranted to provide more conclusive evidence regarding its efficacy in improving clinical outcomes for these patients. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Abbreviations Dexmedetomidine Ventilator-associated pneumonia Intensive care unit The Multiparameter Intelligent Monitoring in Intensive Care Body mass index Simplified Acute Physiology Score II Sequential Organ Failure Assessment Glasgow Coma Score Charlson comorbidity index Continuous Renal Replacement Therapy Myocardial infarction Congestive heart failure Cerebrovascular disease Heart rate Respiration rate Odds ratio Confidence interval Richmond Agitation-Sedation Scale Author contributions MW conceived this research, formulated the research plan, participated in data collection and collation, and wrote the first draft; further collect and organize the data based on the reviewers’ comments, and supplement the manuscript. BL participated in formulating the research plan, conducted statistical analysis, and revised the manuscript; further analyze the supplementary data and further revise the manuscript. ML participated in the data integration during the manuscript revision process. FL critically reviewed, edited, and approved the manuscript; and further revise the manuscript and review it. All authors read and approved the final manuscript. Funding This work was supported by the Guangxi Science and Technology Base and Talent Special Project (GUIKEAD22035047). Data availability Publicly accessible datasets were investigated in the research. This details can be obtainable on the MIMIC-IV website at https://physionet.org/content/mimiciv/3.0/. Declarations Consent for publication All authors of the manuscript agreed to its publication. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Meixu Wang and Bing Lin are contributed equally to this work. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement Publicly accessible datasets were investigated in the research. This details can be obtainable on the MIMIC-IV website at https://physionet.org/content/mimiciv/3.0/.